Jaguar Health targets mid-2027 NDA filing for MVID, sees potential U.S. approval by end-2027 after up to 48% cut in parenteral support

Jaguar Health's timeline targets a mid-2027 NDA submission for MVID with potential U.S. approval by end-2027, supported by trial results indicating up to 48% reductions in parenteral nutrition requirements. While clinically notable, the catalyst is distant and company-specific, limiting near-term cross-asset implications. The update primarily affects idiosyncratic biotech risk appetite rather than broad macro or crypto pricing.